CERECOR (U.S. Trademark Serial Number 88424870) is a United States trademark of AVALO THERAPEUTICS, INC.. The goods and services include: Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington’s disease, insomnia, Parkinson’s disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson’s Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders . The correspondent is Paul J. Kennedy of Troutman Pepper Hamilton Sanders LLP.
This trademark was filed on May 10, 2019 as United States Trademark Application Serial Number 88424870. This trademark application is still pending and does not yet have a registration number.
Trademark PTO Status History
July 04, 2022 – ABANDONMENT – NO USE STATEMENT FILED
December 03, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
December 01, 2021 – SOU EXTENSION 4 GRANTED
December 01, 2021 – SOU EXTENSION 4 FILED
December 01, 2021 – TEAS EXTENSION RECEIVED
September 22, 2021 – AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 22, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 20, 2021 – SOU EXTENSION 3 GRANTED
View full trademark status information at USPTO
Ownership History
AVALO THERAPEUTICS, INC.
Cerecor Inc.
Cerecor Inc.
View documents on file at USPTO
File a Trademark or Get Help With Trademark Law
Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.